Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. [electronic resource]
Producer: 20100304Description: 723-30 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Biomarkers, Tumor -- blood
- Breast Neoplasms -- drug therapy
- Cyclophosphamide -- administration & dosage
- Dalteparin -- administration & dosage
- Disease-Free Survival
- Drug Administration Schedule
- Female
- Humans
- Kaplan-Meier Estimate
- Methotrexate -- administration & dosage
- Middle Aged
- Ontario -- epidemiology
- Prednisone -- administration & dosage
- Time Factors
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- blood
- Vascular Endothelial Growth Factor Receptor-1 -- blood
- Vascular Endothelial Growth Factor Receptor-2 -- blood
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.